GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » 5-Day RSI

Microbix Biosystems (TSX:MBX) 5-Day RSI : 83.00 (As of Dec. 11, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-12-11), Microbix Biosystems's 5-Day RSI is 83.00.

The industry rank for Microbix Biosystems's 5-Day RSI or its related term are showing as below:

TSX:MBX's 5-Day RSI is ranked worse than
95.93% of 1525 companies
in the Biotechnology industry
Industry Median: 46.22 vs TSX:MBX: 83.00

Competitive Comparison of Microbix Biosystems's 5-Day RSI

For the Biotechnology subindustry, Microbix Biosystems's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's 5-Day RSI falls into.



Microbix Biosystems  (TSX:MBX) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems  (TSX:MBX) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Microbix Biosystems 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.
Executives
Cameron Lionel Groome Director, Senior Officer
Bo Hollas Director
Steven Trevor Hagerman Senior Officer
Jennifer Anne Stewart Director
James Stuart Currie Senior Officer
Damian Klimaszewski Senior Officer
Kenneth Hughes Senior Officer
Anthony J. Giovinazzo Director
Martin Marino Director
Mark Adrian Luscher Senior Officer
Peter Martin Blecher Director